Skip to main content

Published locations for Lebrikizumab compared with dupilumab leads to equal or superior long-term outcomes in AD

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Lebrikizumab compared with dupilumab leads to equal or superior long-term outcomes in AD

User login

  • Reset your password
  • /content/lebrikizumab-compared-dupilumab-leads-equal-or-superior-long-term-outcomes-ad
  • /dermatology/article/266522/atopic-dermatitis/lebrikizumab-compared-dupilumab-leads-equal-or-superior